373 related articles for article (PubMed ID: 10689749)
1. [New developments in therapy of chronic hepatitis B. When are nucleoside analogs indicated?].
Petry W; Erhardt A; Heintges T; Häussinger D
Z Gastroenterol; 2000 Jan; 38(1):77-87. PubMed ID: 10689749
[TBL] [Abstract][Full Text] [Related]
2. Chronic hepatitis B--treatment with nucleoside analogues.
Leung N
Med J Malaysia; 2005 Jul; 60 Suppl B():22-7. PubMed ID: 16108169
[TBL] [Abstract][Full Text] [Related]
3. Treatment of chronic hepatitis B: case selection and duration of therapy.
Leung N
J Gastroenterol Hepatol; 2002 Apr; 17(4):409-14. PubMed ID: 11982721
[TBL] [Abstract][Full Text] [Related]
4. Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study.
Pellicelli AM; Barbaro G; Francavilla R; Romano M; Barbarini G; Mazzoni E; Mecenate F; Paffetti A; Barlattani A; Struglia C; Villani R; Nauri L; Nosotti L; Armignacco O; Ferri F; Camporiondo MP; Soccorsi F;
Clin Ther; 2008 Feb; 30(2):317-23. PubMed ID: 18343270
[TBL] [Abstract][Full Text] [Related]
5. Severe exacerbation of chronic hepatitis B after emergence of lamivudine resistance in a cirrhotic patient: immediate switch to adefovir dipivoxil appears to be indicated.
Wiegand J; Tischendorf JJ; Nashan B; Klempnauer J; Flemming P; Niemann P; Rohde P; Manns MP; Trautwein C; Tillmann HL
Z Gastroenterol; 2004 Jan; 42(1):15-8. PubMed ID: 14997399
[TBL] [Abstract][Full Text] [Related]
6. Long-term therapy with adefovir dipivoxil in hepatitis B e antigen-negative patients developing resistance to lamivudine.
Manolakopoulos S; Bethanis S; Koutsounas S; Goulis J; Vlachogiannakos J; Christias E; Saveriadis A; Pavlidis C; Triantos C; Christidou A; Papatheodoridis G; Karamanolis D; Tzourmakliotis D
Aliment Pharmacol Ther; 2008 Feb; 27(3):266-73. PubMed ID: 17988233
[TBL] [Abstract][Full Text] [Related]
7. Treatment of chronic hepatitis B: Evolution over two decades.
Yuen MF; Lai CL
J Gastroenterol Hepatol; 2011 Jan; 26 Suppl 1():138-43. PubMed ID: 21199525
[TBL] [Abstract][Full Text] [Related]
8. Adefovir plus lamivudine are more effective than adefovir alone in lamivudine-resistant HBeAg- chronic hepatitis B patients: a 4-year study.
Vassiliadis TG; Giouleme O; Koumerkeridis G; Koumaras H; Tziomalos K; Patsiaoura K; Grammatikos N; Mpoumponaris A; Gkisakis D; Theodoropoulos K; Panderi A; Katsinelos P; Eugenidis N
J Gastroenterol Hepatol; 2010 Jan; 25(1):54-60. PubMed ID: 19780875
[TBL] [Abstract][Full Text] [Related]
9. A multi-center open study to determine the effect of lamivudine on HBV DNA clearance and to assess the safety of the regimen in patients with chronic hepatitis B infection.
Mazur W; Król F; Cianciara J; Nazzal K; Gładysz A; Juszczyk J; Bolewska B; Adamek J; Czajka B; Swietek K; Kryczka W; Gonciarz Z
Med Sci Monit; 2002 Apr; 8(4):CR257-62. PubMed ID: 11951067
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic options for chronic hepatitis B: considerations and controversies.
Jacobson IM
Am J Gastroenterol; 2006; 101 Suppl 1():S13-8. PubMed ID: 16448447
[TBL] [Abstract][Full Text] [Related]
11. Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues.
Reijnders JG; Deterding K; Petersen J; Zoulim F; Santantonio T; Buti M; van Bömmel F; Hansen BE; Wedemeyer H; Janssen HL;
J Hepatol; 2010 Apr; 52(4):493-500. PubMed ID: 20185191
[TBL] [Abstract][Full Text] [Related]
12. Treatment of chronic viral hepatitis.
Ferenci P
Best Pract Res Clin Gastroenterol; 2004; 18 Suppl():113-20. PubMed ID: 15588803
[TBL] [Abstract][Full Text] [Related]
13. Lamivudine monoprophylaxis and adefovir salvage for liver transplantation in chronic hepatitis B: a seven-year follow-up study.
Limquiaco JL; Wong J; Wong VW; Wong GL; Tse CH; Chan HY; Kwan KY; Lai PB; Chan HL
J Med Virol; 2009 Feb; 81(2):224-9. PubMed ID: 19107976
[TBL] [Abstract][Full Text] [Related]
14. Chronic hepatitis B: a wider range of therapeutic options.
Prescrire Int; 2007 Aug; 16(90):157-62. PubMed ID: 17724844
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis B therapy in children.
Kurbegov AC; Sokol RJ
Expert Rev Gastroenterol Hepatol; 2009 Feb; 3(1):39-49. PubMed ID: 19210112
[TBL] [Abstract][Full Text] [Related]
16. Treatment of HBeAg-negative chronic hepatitis B.
Hadziyannis SJ; Papatheodoridis GV; Vassilopoulos D
Semin Liver Dis; 2003 Feb; 23(1):81-8. PubMed ID: 12616453
[TBL] [Abstract][Full Text] [Related]
17. [Factors associated with response to lamivudine: retrospective study of 233 patients with chronic hepatitis B].
Zhou HJ; Li SG; Wen FY; Yang XY; Wu JL; Tan B; Fu J
Zhonghua Gan Zang Bing Za Zhi; 2009 Aug; 17(8):564-8. PubMed ID: 19719911
[TBL] [Abstract][Full Text] [Related]
18. Advances in therapy for chronic hepatitis B.
Marcellin P
Semin Liver Dis; 2002; 22 Suppl 1():33-6. PubMed ID: 12447727
[TBL] [Abstract][Full Text] [Related]
19. Treatment of chronic hepatitis B: interferon alfa first.
Prescrire Int; 2001 Feb; 10(51):17-21. PubMed ID: 11503853
[TBL] [Abstract][Full Text] [Related]
20. Antiviral therapy in patients with chronic hepatitis B and cirrhosis.
Lai CJ; Terrault NA
Gastroenterol Clin North Am; 2004 Sep; 33(3):629-54, x-xi. PubMed ID: 15324948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
